Dr. Reddy’s Laboratories, an Indian pharma company, has launched Fluphenazine Hydrochloride Tablets, USP, in the US market.

Fluphenazine Hydrochloride Tablets, USP is a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, which has approval from the US Food and Drug Administration (FDA) for the management of manifestations of psychotic disorders.

The Prolixin brand and generic had sales of around $134 million MAT in the US for the most recent 12 months ending in December 2020 as per IQVIA National Sales Perspective: Retail and Non-Retail MAT December 2020.

Dr. Reddy’s Laboratories said that its Fluphenazine Hydrochloride Tablets, USP are available in 100 bottle count sizes in the dosages of 1 mg, 2.5 mg, 5 mg, and 10 mg tablets.

  Dr. Reddy’s Laboratories, Fluphenazine Hydrochloride Tablets, Prolixin, psychotic disorders, USA